Lice are parasitic insects that can be found on people's heads and bodies, including the pubic area. There are three types of lice that affect humans: body lice, head lice, and pubic lice. Lice are tiny, wingless insects that feed on human blood. Lice spread from person to person through close contact and by sharing belongings. Unless treated properly, this condition can become a recurring problem. Lice treatment products are available over-the-counter (OTC) and/or with a prescription. These products help eliminate lice. Head lice survive and thrive solely on human blood, once they’re separated from the human host, they starve and perish within several hours. Nits (head lice eggs), on the other hand, generally die within a week of being released from their human host. While it’s true that an infestation of head lice is inconvenient and perhaps uncomfortable, it’s usually harmless.
Market Dynamics
Increasing prevalence of lice infestation, easy availability of lice treatment products, and a rise in awareness among people are some major factors expected to aid in the growth of the global lice treatment market during the forecast period. In October 2020, the U.S. Food and Drug Administration (FDA) approved a lotion to treat head lice for nonprescription, or over-the-counter (OTC), use through a process called a prescription (Rx)-to-OTC switch. The U.S. FDA initially approved Sklice (ivermectin) lotion, 0.5% for the treatment of head lice in patients 6 months of age and older as a prescription drug in February 2012.
Key features of the study:
- This report provides an in-depth analysis of the global lice treatment market and provides market size (US$ Mn) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global lice treatment market based on the following parameters– company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Fleming Medical Ltd, ParaPRO, LLC, Prestige Consumer Healthcare Inc., Omega Pharma (A subsidiary of Perrigo Company plc), Alliance Pharma PLC, Oystershell, Johnson & Johnson Private Limited, GSK plc, and Arbor Pharmaceuticals Inc. (A subsidiary of Azurity Pharmaceuticals, Inc.)
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global lice treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global lice treatment market.
Detailed Segmentation:
- Global Lice Treatment Market, By Product Type:
- OTC Medication
- Permethrin
- Pyrethrin
- Other Product Types
- Prescription Medication
- Ivermectin
- Spinosad
- Malathion
- Other Prescription Medications
- Global Lice Treatment Market, By Distribution Channel:
- Hospitals And Clinics
- Retail Pharmacies
- Other Distribution Channels
- Global Lice Treatment Market, By Geography:
- North America
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Fleming Medical Ltd
- ParaPRO, LLC
- Prestige Consumer Healthcare Inc.
- Omega Pharma (A subsidiary of Perrigo Company plc)
- Alliance Pharma PLC
- Oystershell
- Johnson & Johnson Private Limited
- GSK plc
- Arbor Pharmaceuticals Inc. (A subsidiary of Azurity Pharmaceuticals, Inc.)
